PL446872A1 - Kompozycja farmaceutyczna do zapobiegania i łagodzenia wczesnych odczynów skórnych wywołanych napromieniowaniem u pacjentów leczonych z powodu nowotworów - Google Patents

Kompozycja farmaceutyczna do zapobiegania i łagodzenia wczesnych odczynów skórnych wywołanych napromieniowaniem u pacjentów leczonych z powodu nowotworów

Info

Publication number
PL446872A1
PL446872A1 PL446872A PL44687223A PL446872A1 PL 446872 A1 PL446872 A1 PL 446872A1 PL 446872 A PL446872 A PL 446872A PL 44687223 A PL44687223 A PL 44687223A PL 446872 A1 PL446872 A1 PL 446872A1
Authority
PL
Poland
Prior art keywords
cancer
preventing
pharmaceutical composition
skin reactions
patients undergoing
Prior art date
Application number
PL446872A
Other languages
English (en)
Inventor
Emilia JAREMKO-PIEKARSKA
Magdalena Biegaj
Hubert Ćwiklewski
Dorota Kiprian
Original Assignee
Verco Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verco Spółka Akcyjna filed Critical Verco Spółka Akcyjna
Priority to PL446872A priority Critical patent/PL446872A1/pl
Priority to EP24215950.7A priority patent/EP4566589A1/en
Publication of PL446872A1 publication Critical patent/PL446872A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89—Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem wynalazku jest kompozycja farmaceutyczna do zastosowania w zapobieganiu łagodzeniu wczesnych odczynów skórnych wywołanych napromienianiem u chorych leczonych z powodu nowotworów, składająca się z fazy wodnej i fazy silikonowej, podczas gdy faza wodna obejmuje co najmniej jeden rozpuszczalny w wodzie związek będący źródłem jonów cynku, a zawartość fazy silikonowej w kompozycji wynosi nie mniej niż 10% wag.
PL446872A 2023-11-27 2023-11-27 Kompozycja farmaceutyczna do zapobiegania i łagodzenia wczesnych odczynów skórnych wywołanych napromieniowaniem u pacjentów leczonych z powodu nowotworów PL446872A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL446872A PL446872A1 (pl) 2023-11-27 2023-11-27 Kompozycja farmaceutyczna do zapobiegania i łagodzenia wczesnych odczynów skórnych wywołanych napromieniowaniem u pacjentów leczonych z powodu nowotworów
EP24215950.7A EP4566589A1 (en) 2023-11-27 2024-11-27 Pharmaceutical composition for prevention and alleviation of early skin reactions caused by irradiation in patients treated for cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL446872A PL446872A1 (pl) 2023-11-27 2023-11-27 Kompozycja farmaceutyczna do zapobiegania i łagodzenia wczesnych odczynów skórnych wywołanych napromieniowaniem u pacjentów leczonych z powodu nowotworów

Publications (1)

Publication Number Publication Date
PL446872A1 true PL446872A1 (pl) 2025-06-02

Family

ID=95398890

Family Applications (1)

Application Number Title Priority Date Filing Date
PL446872A PL446872A1 (pl) 2023-11-27 2023-11-27 Kompozycja farmaceutyczna do zapobiegania i łagodzenia wczesnych odczynów skórnych wywołanych napromieniowaniem u pacjentów leczonych z powodu nowotworów

Country Status (2)

Country Link
EP (1) EP4566589A1 (pl)
PL (1) PL446872A1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191189A1 (en) * 2000-04-05 2004-09-30 Jean-Christophe Choulot Sunscreen milk
US20070264292A1 (en) * 2004-02-19 2007-11-15 Takafumi Kurosawa Sun-Block Cosmetic
WO2017109761A1 (en) * 2015-12-23 2017-06-29 Dr. Reddy's Laboratories Ltd Topical composition for the treatment of acne

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030204A1 (it) 2003-04-29 2004-10-30 Provincia Italiana Della Congregazi One Dei Figli Formulazione dermatologica.
FR3010906B1 (fr) * 2013-09-25 2016-12-23 Expanscience Lab Extrait lipidique de graines de passiflores
CN106109320A (zh) 2016-07-28 2016-11-16 扬中市锦丰工业设计有限公司 保湿化妆水
JP6586192B1 (ja) 2018-04-27 2019-10-02 株式会社光洋 皮膚保護用組成物
WO2021167810A1 (en) * 2020-02-21 2021-08-26 Anjon Biologics, Inc. Compositions for skincare and use thereof
KR102513829B1 (ko) 2022-07-18 2023-03-27 주식회사 코스메카코리아 무방부제 화장료 조성물 및 이의 제조 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191189A1 (en) * 2000-04-05 2004-09-30 Jean-Christophe Choulot Sunscreen milk
US20070264292A1 (en) * 2004-02-19 2007-11-15 Takafumi Kurosawa Sun-Block Cosmetic
WO2017109761A1 (en) * 2015-12-23 2017-06-29 Dr. Reddy's Laboratories Ltd Topical composition for the treatment of acne

Also Published As

Publication number Publication date
EP4566589A1 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
Imai et al. Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases
Zhu et al. Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy
Flickinger et al. Does increased nerve length within the treatment volume improve trigeminal neuralgia radiosurgery? A prospective double-blind, randomized study
Poulsen et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?
Flickinger A radiobiological analysis of multicenter data for postoperative keloid radiotherapy
Paoli et al. Nonsurgical options for the treatment of basal cell carcinoma
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
MXPA05010597A (es) Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.
Foo et al. Topical modalities for treatment and prevention of postsurgical hypertrophic scars
Fujisawa et al. Chemoradiation using low-dose cisplatin and 5-fluorouracil in locally advanced squamous cell carcinoma of the skin: a report of two cases
Cooper The influence of dose on the long-term control of classic (non-AIDS associated) Kaposi's Sarcoma by radiotherapy
Valcarenghi et al. Mepitel® film versus standard care for the prevention of skin toxicity in breast cancer patients treated with adjuvant radiotherapy: A randomized controlled trial
Khong et al. Non-melanoma skin cancer in general practice: Radiotherapy is an effective treatment option
Slabbert et al. Increased proton relative biological effectiveness at the very end of a spread-out Bragg peak for jejunum irradiated ex vivo
Haffty Radiation therapy and the risk of contralateral breast cancer
Raju P et al. A Study to Evaluate the Effectiveness of Continuous Ultrasound Therapy in Healing of Pressure Sores-A Prospective Randomized Clinical Trial.
Suh et al. Using recombinant human epidermal growth factor for the successful treatment of an excisional wound without a primary closure
DE602004015146D1 (de) Verwendung von 4-hydroxytamoxifen zur herstellung eines medikaments zur behandlung von gynäkomastie
van derBoon New drug slows prostate-cancer progression
Munteanu et al. Use of gentian violet in the treatment of severe radiodermatitis secondary to adjuvant radiotherapy in breast cancer
Villaquiran Effects of Radiation Therapy on Skin and Folds: Methods to Identify, Prevent, and Care for Reactions.
RU2694536C2 (ru) Способ лечения кожных заболеваний, ожогов, поверхностных и глубоких ран
Moens et al. ID# 1904695 A cost-effective solution for neuromodulation device implantation in patients suffering from titanium oxalate allergy
Ferrero et al. The stomized, chemo and radiotreated patient vs untreated patient: Complications and comparison with data literature
Marquez-Arreguin et al. A Phase I Trial of CC-486, Lenalidomide, Obinutuzumab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma